TKNO

Alpha Teknova, Inc.

$8.73

2.11%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc.

Source: Yahoo Finance
AI summary

Price & performance

1M-12.4%
3M+40.5%
YTD+102.1%
1Y+59.2%
52-week range—
Beta1.34
Full chart and returns against a benchmark

Q-Score

56/ 100

Quality against peers; 50 is the peer median.

Growth61
Risk48
Performance72
Valuation40
Profitability49
Leverage54
Sentiment82
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$40.5M+7.4%
Net income-$17.3M
Net margin-42.6%+28.3 pts
Historical fundamentals

Revenue exposure

6%of revenue from outside the US
United States94%
Non Us6%
Largest customer21%
Regions, segments, customers and suppliers

Valuation

TKNOIndustryP/E—35.25P/S11.952.74EV/EBITDA—16.35P/B9.192.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report
EPS estimate$-0.05
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate